INTRODUCTIONIn addition to its importance in reproductive medicine and gynaecology, polycystic ovary syndrome (PCOS) is recognized to confer an adverse cardiometabolic risk profile and to predispose to Type 2 diabetes and probably cardiovascular disease. For this reason, most guidelines for management of women with PCOS recommend regular screening for dysglycaemia and cardiovascular risk factors.However, it is clear that many women with PCOS, particularly those of normal BMI (body mass index), do not progress to prediabetes or diabetes (9). While there is evidence of increased subclinical atherosclerosis and abnormalities in cardiac morphology and function in women with PCOS, whether this translates into an increased number of cardiovascular events and higher mortality remains contentious. In addition, nonobese women with PCOS have been shown to have normal cardiovascular function. Application of blanket guidelines to all women with PCOS potentially leads to unnecessary anxiety and over‐investigation in these low‐risk women. In contrast, there are many women with ovulatory menstrual cycles and without clinical or biochemical evidence of hyperandrogenism, who are at significant risk of diabetes and cardiovascular disease due to obesity and would benefit from appropriate interventions to recognize and improve risk factors.The use of different diagnostic criteria for PCOS further adds to
Clinical Endocrinology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera